Maximum rates of TAT formation, FPA generation, and osteonectin release during TF-initiated (25 pM) whole blood clotting
| Agent . | Subject . | Clotting time (min) . | Maximum rate . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TAT (nM/min) . | FPA (μM/min) . | Osteonectin (nM/min) . | |||||||
| C . | E . | C . | E . | C . | E . | C . | E . | ||
| TRAP | 2 | 3.1 | 2.3 | 149 | 136 | — | — | 8.2 | 8.0 |
| 5 μM | 6 | 4.7 | 4.2 | 94 | 122 | — | — | 3.9 | 4.0 |
| Average | 3.9 | 3.3 | 122 | 129 | — | — | 6.0 | 6.0 | |
| PGE1 | 1 | 4.2 | 10.7 | 70 | 35 | 6.0 | 5.2 | 9.9 | 7.5 |
| 5 μM | 2 | 4.4 | 9.3 | 54 | 12 | 3.4 | 3.2 | 11.8 | 9.0 |
| Average | 4.3 | 10.0 | 62 | 24 | 4.7 | 4.2 | 10.8 | 8.2 | |
| ASA | 1 | 4.2 | 3.7 | 63 | 53 | 7.6 | 2.7 | 6.5 | 3.9 |
| 2 × 325 mg/d | 2 | 3.1 | 4.1 | 51 | 46 | 4.6 | 2.7 | 5.5 | 2.7 |
| 3 | 5.1 | 3.6 | 105 | 102 | 3.2 | 7.5 | 4.7 | 4.7 | |
| Average | 4.1 | 3.8 | 73 | 67 | 5.1 | 4.3 | 5.6 | 3.8 | |
| Dipyridamole | 4 | 4.2 | 4.5 | 64 | 99 | — | — | 9.7 | 16.8 |
| 5 μM | 5 | 6.0 | 6.1 | 98 | 83 | 9.7 | 10.1 | 14.5 | 21.3 |
| Average | 5.1 | 5.3 | 81 | 91 | 9.7 | 10.1 | 12.1 | 19.0 | |
| 7E3 | 1 | 5.0 | 6.5 | 67 | 42 | 11.4 | 4.6 | 6.5 | 7.1 |
| 10 μg/mL | 2 | 3.1 | 3.7 | 51 | 31 | 4.6 | 5.2 | 7.8 | 10.5 |
| Average | 4.0 | 5.1 | 59 | 36 | 8.0 | 4.9 | 7.1 | 8.8 | |
| Reopro | 1 | 4.0 | 5.9 | 73 | 47 | 8.3 | 4.2 | 13.0 | 8.1 |
| 10 μg/mL | 2 | 4.5 | 6.7 | 90 | 27 | 5.4 | 4.1 | 4.1 | 4.0 |
| Average | 4.2 | 6.3 | 81 | 37 | 6.8 | 4.1 | 8.6 | 6.0 | |
| Integrin | 1 | 4.2 | 4.8 | 76 | 18 | 8.2 | 4.5 | 5.9 | 9.3 |
| 5 μM | 2 | 3.7 | 4.3 | 43 | 26 | 10.5 | 4.0 | 16.8 | 16.5 |
| Average | 3.9 | 4.5 | 59 | 22 | 9.3 | 4.2 | 11.3 | 12.9 | |
| Agent . | Subject . | Clotting time (min) . | Maximum rate . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TAT (nM/min) . | FPA (μM/min) . | Osteonectin (nM/min) . | |||||||
| C . | E . | C . | E . | C . | E . | C . | E . | ||
| TRAP | 2 | 3.1 | 2.3 | 149 | 136 | — | — | 8.2 | 8.0 |
| 5 μM | 6 | 4.7 | 4.2 | 94 | 122 | — | — | 3.9 | 4.0 |
| Average | 3.9 | 3.3 | 122 | 129 | — | — | 6.0 | 6.0 | |
| PGE1 | 1 | 4.2 | 10.7 | 70 | 35 | 6.0 | 5.2 | 9.9 | 7.5 |
| 5 μM | 2 | 4.4 | 9.3 | 54 | 12 | 3.4 | 3.2 | 11.8 | 9.0 |
| Average | 4.3 | 10.0 | 62 | 24 | 4.7 | 4.2 | 10.8 | 8.2 | |
| ASA | 1 | 4.2 | 3.7 | 63 | 53 | 7.6 | 2.7 | 6.5 | 3.9 |
| 2 × 325 mg/d | 2 | 3.1 | 4.1 | 51 | 46 | 4.6 | 2.7 | 5.5 | 2.7 |
| 3 | 5.1 | 3.6 | 105 | 102 | 3.2 | 7.5 | 4.7 | 4.7 | |
| Average | 4.1 | 3.8 | 73 | 67 | 5.1 | 4.3 | 5.6 | 3.8 | |
| Dipyridamole | 4 | 4.2 | 4.5 | 64 | 99 | — | — | 9.7 | 16.8 |
| 5 μM | 5 | 6.0 | 6.1 | 98 | 83 | 9.7 | 10.1 | 14.5 | 21.3 |
| Average | 5.1 | 5.3 | 81 | 91 | 9.7 | 10.1 | 12.1 | 19.0 | |
| 7E3 | 1 | 5.0 | 6.5 | 67 | 42 | 11.4 | 4.6 | 6.5 | 7.1 |
| 10 μg/mL | 2 | 3.1 | 3.7 | 51 | 31 | 4.6 | 5.2 | 7.8 | 10.5 |
| Average | 4.0 | 5.1 | 59 | 36 | 8.0 | 4.9 | 7.1 | 8.8 | |
| Reopro | 1 | 4.0 | 5.9 | 73 | 47 | 8.3 | 4.2 | 13.0 | 8.1 |
| 10 μg/mL | 2 | 4.5 | 6.7 | 90 | 27 | 5.4 | 4.1 | 4.1 | 4.0 |
| Average | 4.2 | 6.3 | 81 | 37 | 6.8 | 4.1 | 8.6 | 6.0 | |
| Integrin | 1 | 4.2 | 4.8 | 76 | 18 | 8.2 | 4.5 | 5.9 | 9.3 |
| 5 μM | 2 | 3.7 | 4.3 | 43 | 26 | 10.5 | 4.0 | 16.8 | 16.5 |
| Average | 3.9 | 4.5 | 59 | 22 | 9.3 | 4.2 | 11.3 | 12.9 | |
C indicates control; E, experiment.